Beneficial effects of muscone on cardiac remodeling in a mouse model of myocardial infarction

International Journal of Molecular Medicine

Volumn 34, Issue 1, 2014, Pages 103-111

  Wang, Xiaoyan ^a,b   Meng, Haoyu ^a   Chen, Pengsheng ^a   Yang, Naiquan ^c   Lu, Xin ^a   Wang, Ze Mu ^a   Gao, Wei ^a   Zhou, Ningtian ^a   Zhang, Min ^a   Xu, Zhihui ^a   Chen, Bo ^a   Tao, Zhengxian ^a   Wang, Liangsheng ^a   Yang, Zhijian ^a   Zhu, Tiebin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Mouse model; Muscone; Myocardial infarction; Myocardial remodeling

Indexed keywords

COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MUSCONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CARDIOTONIC AGENT; CYCLOALKANE DERIVATIVE; NOS3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG MECHANISM; EXERCISE TOLERANCE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART WEIGHT; INFLAMMATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWIMMING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ENDURANCE; FIBROSIS; GENE EXPRESSION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; MALE; METABOLISM; MYOCARDIAL INFARCTION; ORGAN SIZE; PATHOLOGY;

ANIMALS; BODY WEIGHT; CARDIOTONIC AGENTS; CYCLOPARAFFINS; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION; HEART VENTRICLES; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL ENDURANCE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84902661664     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1766     Document Type: Article

References (46)

1. Lin DL, Chang HC and Huang SH: Characterization of allegedly musk-containing medicinal products in Taiwan. J Forensic Sci 49: 1187-1193, 2004.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D and Turner MB: Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127: e6-e245, 2013.
3. Hung J, Teng TH, Finn J, Knuiman M, Briffa T, Stewart S, Sanfilippo FM, Ridout S and Hobbs M: Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia. J Am Heart Assoc 2: e000172, 2013.
4. Sun Y, Zhang JQ, Zhang J and Lamparter S: Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 135: 316-323, 2000. (Pubitemid 30213547)
5. See F, Kompa A, Martin J, Lewis DA and Krum H: Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Des 11: 477-487, 2005. (Pubitemid 40207758)
6. Tucci PJ: Pathophysiological characteristics of the post-myocardial infarction heart failure model in rats. Arq Bras Cardiol 96: 420-424, 2011.
7. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P and Lee RT: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999. (Pubitemid 29270438)
8. Lindsey ML, Mann DL, Entman ML and Spinale FG: Extracellular matrix remodeling following myocardial injury. Ann Med 35: 316-326, 2003. (Pubitemid 37013672)
9. Yan SK, Zhang WD, Liu RH and Zhan YC: Chemical finger-printing of Shexiang Baoxin Pill and simultaneous determination of its major constituents by HPLC with evaporative light scattering detection and electrospray mass spectrometric detection. Chem Pharm Bull (Tokyo) 54: 1058-1062, 2006.
10. Shen W, Fan WH and Shi HM: Effects of shexiang baoxin pill on angiogenesis in atherosclerosis plaque and ischemic myocardium. Zhongguo Zhong Xi Yi Jie He Za Zhi 30: 1284-1287, 2010 (In Chinese).
11. Fan X, Shi M, Wang Y, Liang Q and Luo G: Transcriptional profiling analysis of HMP-treated rats with experimentally induced myocardial infarction. J Ethnopharmacol 137: 199-204, 2011.
12. Wu DJ, Hong HS and Jiang Q: Effect of shexiang baoxin pill in alleviating myocardial fibrosis in spontaneous hypertensive rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 25: 350-353, 2005 (In Chinese).
13. Cai YM, He Y, Qiu T, Zou J, Sun DP, Peng QH, Jia RX and Zhao HR: Research on frequency of application with modern Chinese herbal medicine. Chin J Integr Med 17: 64-70, 2011.
14. Wang LJ, Luo XP and Wang Y: Evaluation on tolerability and safety of long-term administration with shexiang baoxin pill in patients with coronary heart disease of stable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 399-401, 2008 (In Chinese).
15. Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, Fan W, Dai R and Hu Z: Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts. Life Sci 74: 2467-2478, 2004. (Pubitemid 38324603)
16. Xiang L, Jiang P, Zhan C, Chen Z, Liu X, Huang X, Wang S, Hu Y, Zhang W and Liu R: The serum metabolomic study of intervention effects of the traditional Chinese medicine Shexiang Baoxin Pill and a multi-component medicine polypill in the treatment of myocardial infarction in rats. Mol Biosyst 8: 2434-2442, 2012.
17. Sun R, Zhang ZP, Huang W, Lv LP and Ren HY: Protective effects of muskone on rats with complete cerebral ischemia. Trad Chin Drug Res Clin Pharmacol 20: 197-200, 2009 (In Chinese).
18. Wei G, Chen DF, Lai XP, Liu DH, Deng RD, Zhou JH, Zhang SX, Li YW, Li H and Zhang QD: Muscone exerts neuroprotection in an experimental model of stroke via inhibition of the fas pathway. Nat Prod Commun 7: 1069-1074, 2012.
19. Tanaka E, Funae Y, Imaoka S and Misawa S: Characterization of liver microsomal cytochrome P450 from rats treated with muscone (3- methylcyclopentadecanone). Biochem Pharmacol 41: 472-473, 1991.
20. Wu Q, Li H, Wu Y, Shen W, Zeng L, Cheng H and He L: Protective effects of muscone on ischemia-reperfusion injury in cardiac myocytes. J Ethnopharmacol 138: 34-39, 2011.
21. Hori M and Nishida K: Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81: 457-464, 2009.
22. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L and Badimon L: Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 50: 522-533, 2011.
23. Yang C, Talukder MA, Varadharaj S, Velayutham M and Zweier JL: Early ischaemic preconditioning requires Akt- and PKA-mediated activation of eNOS via serine1176 phosphorylation. Cardiovasc Res 97: 33-43, 2013.
24. Chen LL, Zhu TB, Yin H, Huang J, Wang LS, Cao KJ and Yang ZJ: Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation. Mol Biol Rep 37: 3067-3072, 2010.
25. Wu JX, Liang C and Ren YS: Effects of shexiang baoxin pill on function and nitric oxide secretion of endothelial progenitor cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 511-513, 2009 (In Chinese).
26. Salto-Tellez M, Yung Lim S, El-Oakley RM, Tang TP, Za AL and Lim SK: Myocardial infarction in the C57BL/6J mouse: a quantifiable and highly reproducible experimental model. Cardiovasc Pathol 13: 91-97, 2004. (Pubitemid 38366427)
27. Liang H and Luo BY: The study of muscone on attenuating excitotoxicity during acute cerebral ischemia. Zhong Yao Yao Li Yu Lin Chuang 21: 12-13, 2005 (In Chinese).
28. Vivar R, Humeres C, Ayala P, Olmedo I, Catalan M, Garcia L, Lavandero S and Diaz-Araya G: TGF-beta1 prevents simulated ischemia/reperfusion-induced cardiac fibroblast apoptosis by activation of both canonical and non-canonical signaling pathways. Biochim Biophys Acta 1832: 754-762, 2013.
29. Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K and Becker LC: Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 48: 320-328, 2006. (Pubitemid 46066838)
30. Siwik DA, Chang DL and Colucci WS: Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259-1265, 2000. (Pubitemid 30436667)
31. Stephenson D, Yin T, Smalstig EB, Hsu MA, Panetta J, Little S and Clemens J: Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J Cereb Blood Flow Metab 20: 592-603, 2000. (Pubitemid 30164903)
32. Ogawa K, Chen F, Kuang C and Chen Y: Suppression of matrix metal-loproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 381: 413-422, 2004. (Pubitemid 38969685)
33. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M and Hori M: Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105: 509-515, 2002. (Pubitemid 34141710)
34. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J and Ogihara T: In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3: 894-899, 1997. (Pubitemid 27353450)
35. Elsasser A, Vogt AM, Nef H, Kostin S, Mollmann H, Skwara W, Bode C, Hamm C and Schaper J: Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J Am Coll Cardiol 43: 2191-2199, 2004. (Pubitemid 38757584)
36. Crow MT, Mani K, Nam YJ and Kitsis RN: The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95: 957-970, 2004. (Pubitemid 39532326)
37. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997. (Pubitemid 27097313)
38. Grimm S, Bauer MK, Baeuerle PA and Schulze-Osthoff K: Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 134: 13-23, 1996. (Pubitemid 26231517)
39. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo JG, Lynch RA, Mann DL, Bolli R and Dorn GW: Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res 96: 1103-1109, 2005. (Pubitemid 40791383)
40. Sharma S, Singh M and Sharma PL: Mechanism of hyperhomocysteinemia- induced vascular endothelium dysfunction - possible dysregulation of phosphatidylinositol-3-kinase and its downstream phosphoinositide dependent kinase and protein kinase B. Eur J Pharmacol 721: 365-372, 2013.
41. Yasuda S, Kobayashi H, Iwasa M, Kawamura I, Sumi S, Narentuoya B, Yamaki T, Ushikoshi H, Nishigaki K, Nagashima K, Takemura G, Fujiwara T, Fujiwara H and Minatoguchi S: Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol 296: H1558-H1565, 2009.
42. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A and Sessa WC: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601, 1999.
43. Bell RM and Yellon DM: Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35: 185-193, 2003. (Pubitemid 36269192)
44. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K and Oshita S: Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sci 88: 725-729, 2011.
45. Balakumar P, Kathuria S, Taneja G, Kalra S and Mahadevan N: Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol 52: 83-92, 2012.
46. Zhao X, Lu X and Feng Q: Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. American journal of physiology Am J Physiol Heart Circ Physiol 283: H2371-H2378, 2002. (Pubitemid 35345941)